Marin E Healy1, Jenny D Y Chow1, Frances L Byrne1, David S Breen1, Norbert Leitinger1, Chien Li1, Carolin Lackner2, Stephen H Caldwell3, Kyle L Hoehn4. 1. Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA. 2. Institute of Pathology, Medical University of Graz, Graz, Austria. 3. Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA; Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA 22908, USA. 4. Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA; Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA; Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA 22908, USA; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. Electronic address: klh8st@virginia.edu.
Abstract
BACKGROUND & AIMS: Mice exposed to the hepatocellular carcinogen diethylnitrosamine at 2 weeks of age have a high risk of developing primary liver tumors later in life. Previous studies have demonstrated that diethylnitrosamine-treated mice have increased tumor burden when fed an obesigenic "Western" diet rich in lard fat and sugar. However, the role of dietary fats vs. sugars in the promotion of liver cancer is poorly understood. The aim of this study was to determine how altering dietary fats vs. sugars affects tumor burden in the diethylnitrosamine model. METHODS: C57BL/6N mice were treated with diethylnitrosamine at 2 weeks of age and, from 6 to 32 weeks of age, fed one of five diets that differed in fat and sugar content, including normal chow, ketogenic, and Western diets. RESULTS: Mice fed sugar-rich diets had the greatest tumor burden irrespective of dietary fat content. In contrast, mice fed a high-fat low-sugar diet had the least tumor burden despite obesity and glucose intolerance. When evaluated as independent variables, tumor burden was positively correlated with hepatic fat accumulation, postprandial insulin, and liver IL-6, and inversely correlated with serum adiponectin. In contrast, tumor burden did not correlate with adiposity, fasting insulin, or glucose intolerance. Furthermore, mice fed high sugar diets had lower liver expression of p21 and cleaved caspase-3 compared to mice fed low sugar diets. CONCLUSIONS: These data indicate that dietary sugar intake contributes to liver tumor burden independent of excess adiposity or insulin resistance in mice treated with diethylnitrosamine.
BACKGROUND & AIMS:Mice exposed to the hepatocellular carcinogen diethylnitrosamine at 2 weeks of age have a high risk of developing primary liver tumors later in life. Previous studies have demonstrated that diethylnitrosamine-treated mice have increased tumor burden when fed an obesigenic "Western" diet rich in lard fat and sugar. However, the role of dietary fats vs. sugars in the promotion of liver cancer is poorly understood. The aim of this study was to determine how altering dietary fats vs. sugars affects tumor burden in the diethylnitrosamine model. METHODS: C57BL/6N mice were treated with diethylnitrosamine at 2 weeks of age and, from 6 to 32 weeks of age, fed one of five diets that differed in fat and sugar content, including normal chow, ketogenic, and Western diets. RESULTS:Mice fed sugar-rich diets had the greatest tumor burden irrespective of dietary fat content. In contrast, mice fed a high-fat low-sugar diet had the least tumor burden despite obesity and glucose intolerance. When evaluated as independent variables, tumor burden was positively correlated with hepatic fat accumulation, postprandial insulin, and liver IL-6, and inversely correlated with serum adiponectin. In contrast, tumor burden did not correlate with adiposity, fasting insulin, or glucose intolerance. Furthermore, mice fed high sugar diets had lower liver expression of p21 and cleaved caspase-3 compared to mice fed low sugar diets. CONCLUSIONS: These data indicate that dietary sugar intake contributes to liver tumor burden independent of excess adiposity or insulin resistance in mice treated with diethylnitrosamine.
Authors: Joel R Garbow; Jason M Doherty; Rebecca C Schugar; Sarah Travers; Mary L Weber; Anna E Wentz; Nkiruka Ezenwajiaku; David G Cotter; Elizabeth M Brunt; Peter A Crawford Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-03-31 Impact factor: 4.052
Authors: Melanie Kahle; Marion Horsch; Barbara Fridrich; Anett Seelig; Jürgen Schultheiß; Jörn Leonhardt; Martin Irmler; Johannes Beckers; Birgit Rathkolb; Eckhard Wolf; Nicole Franke; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susanne Neschen Journal: Mol Metab Date: 2013-08-03 Impact factor: 7.422
Authors: Anthony Nicholson; Peter C Reifsnyder; Rachel D Malcolm; Charlotte A Lucas; Grant R MacGregor; Weidong Zhang; Edward H Leiter Journal: Obesity (Silver Spring) Date: 2010-01-07 Impact factor: 5.002
Authors: M Rossi; L Lipworth; L Dal Maso; R Talamini; M Montella; J Polesel; J K McLaughlin; M Parpinel; S Franceschi; P Lagiou; C La Vecchia Journal: Ann Oncol Date: 2009-06-23 Impact factor: 32.976
Authors: Nigel Turner; Krit Hariharan; Jennifer TidAng; Georgia Frangioudakis; Susan M Beale; Lauren E Wright; Xiao Yi Zeng; Simon J Leslie; Jing-Ya Li; Edward W Kraegen; Gregory J Cooney; Ji-Ming Ye Journal: Diabetes Date: 2009-08-31 Impact factor: 9.461
Authors: Marin E Healy; Sujoy Lahiri; Stefan R Hargett; Jenny D Y Chow; Frances L Byrne; David S Breen; Brandon M Kenwood; Evan P Taddeo; Carolin Lackner; Stephen H Caldwell; Kyle L Hoehn Journal: Sci Rep Date: 2016-02-29 Impact factor: 4.379
Authors: Marin E Nelson; Sujoy Lahiri; Jenny D Y Chow; Frances L Byrne; Stefan R Hargett; David S Breen; Ellen M Olzomer; Lindsay E Wu; Gregory J Cooney; Nigel Turner; David E James; Jill K Slack-Davis; Carolin Lackner; Stephen H Caldwell; Kyle L Hoehn Journal: Nat Commun Date: 2017-03-14 Impact factor: 14.919